LEQEMBI IQLIK is now available in the U.S. for early Alzheimer’s disease, offering once-weekly at-home dosing for treatment initiation and maintenance.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Eisai and Biogen announced that LEQEMBI IQLIK®, a once-weekly subcutaneous (SC) injection of lecanemab-irmb, is now available in the U.S. for initiation therapy in adults with early Alzheimer’s disease (AD). Early AD includes adults with mild cognitive impairment (MCI) due to AD or mild dementia due to AD. MCI due to AD is the earliest symptomatic stage of AD and may involve subtle symptoms such as forgetfulness, confusion, or feeling at a loss for words.
In July 2026, the U.S. Food and Drug Administration (FDA) approved LEQEMBI IQLIK as a once-weekly subcutaneous initiation dose for adults with early Alzheimer’s disease, enabling at-home treatment initiation through an autoinjector.
A New Option for Starting Treatment
LEQEMBI IQLIK is administered subcutaneously using an autoinjector, providing an alternative to intravenous (IV) administration from the start of treatment. For initiation therapy, the approved regimen is 500 mg once weekly, given as two consecutive 250 mg injections. Each injection is delivered in approximately 15 seconds.
Initiation and Maintenance Dosing
LEQEMBI IQLIK can also be used for maintenance dosing at 360 mg once weekly after 18 months of IV or SC treatment. Throughout the treatment course, patients may receive LEQEMBI through either IV infusion or SC injection with LEQEMBI IQLIK. Patients may also switch from IV to SC administration, or from SC to IV administration, providing additional flexibility in how treatment is delivered.
At-Home Administration May Reduce Treatment Burden
The availability of LEQEMBI IQLIK for both initiation and maintenance expands the options for administering anti-amyloid therapy. At-home administration may reduce the time patients and their care partners spend attending clinic visits for treatment and may make it easier to continue therapy while traveling. SC administration may also reduce healthcare resources associated with IV dosing, including infusion preparation and nurse monitoring.
These features may help streamline the overall Alzheimer’s disease treatment pathway while giving patients and their care partners greater flexibility in managing treatment.
MRI Monitoring Remains Part of Treatment
As with IV administration, brain magnetic resonance imaging (MRI) is performed before treatment initiation and at specified time points after treatment begins for monitoring of amyloid-related imaging abnormalities (ARIA).
Support for Patients, Care Partners, and Healthcare Providers
Eisai and Biogen are providing resources to support implementation and use of LEQEMBI IQLIK. Patient resources include an Instructions for Use video and an IQLIK Welcome Kit containing a What to Expect Treatment Tracker, injection reminder magnet, and Demo Kit to help patients and care partners prepare for and administer injections at home. The LEQEMBI Companion app will also provide education about the injection process and tools for tracking doses.
Through the LEQEMBI Specialty Pharmacy Network, patients may receive assistance with prescription fulfilment, insurance coverage navigation, onboarding, delivery coordination, and device-use education. Eligible patients may also receive treatment reminders and educational support during the first six months of therapy if they choose to participate.
Healthcare providers will have access to electronic health record support materials and a step-by-step Getting Started Guide covering the process from prescription submission through therapy initiation.
Financial Assistance
Eisai’s Patient Assistance Program (PAP) will provide LEQEMBI and LEQEMBI IQLIK at no cost to eligible uninsured patients who meet financial need and other program criteria.
Reference
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.